Valbiotis SAS (ALVAL)

Currency in EUR
0.830
+0.003(+0.36%)
Closed·
ALVAL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
ALVAL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.8000.833
52 wk Range
0.7201.900
Key Statistics
Prev. Close
0.827
Open
0.827
Day's Range
0.8-0.833
52 wk Range
0.72-1.9
Volume
42.78K
Average Volume (3m)
131.77K
1-Year Change
-37.78%
Book Value / Share
0.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALVAL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.000
Upside
+261.45%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Valbiotis SAS Company Profile

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.

Compare ALVAL to Peers and Sector

Metrics to compare
ALVAL
Peers
Sector
Relationship
P/E Ratio
−1.3x−2.4x−0.5x
PEG Ratio
0.180.040.00
Price/Book
1.3x1.5x2.6x
Price / LTM Sales
74.9x4.7x3.3x
Upside (Analyst Target)
261.4%138.8%43.4%
Fair Value Upside
Unlock8.3%7.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.000
(+261.45% Upside)

Earnings

Latest Release
Mar 03, 2025
EPS / Forecast
-0.21 / --
Revenue / Forecast
-2,000,000.00 / --
EPS Revisions
Last 90 days

ALVAL Income Statement

People Also Watch

70.32
TEPRF
-0.20%
2.2800
ALCPB
+2.47%
32.43
RENA
+2.14%
252.90
ESLX
+0.28%
1.750
ALREW
+1.63%

FAQ

What Stock Exchange Does Valbiotis Trade On?

Valbiotis is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for Valbiotis?

The stock symbol for Valbiotis is "ALVAL."

What Is the Valbiotis Market Cap?

As of today, Valbiotis market cap is 13.18M.

What Is Valbiotis's Earnings Per Share (TTM)?

The Valbiotis EPS (TTM) is -0.63.

From a Technical Analysis Perspective, Is ALVAL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Valbiotis Stock Split?

Valbiotis has split 1 times.

How Many Employees Does Valbiotis Have?

Valbiotis has 44 employees.

What is the current trading status of Valbiotis (ALVAL)?

As of 10 Aug 2025, Valbiotis (ALVAL) is trading at a price of 0.83, with a previous close of 0.83. The stock has fluctuated within a day range of 0.80 to 0.83, while its 52-week range spans from 0.72 to 1.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.